甘李药业股份有限公司关于2022年、2024年限制性股票激励计划部分限制性股票回购注销实施公告

Core Viewpoint - 甘李药业 announced the repurchase and cancellation of 220,300 restricted stocks due to the departure of certain incentive plan participants and performance evaluations [2][5][6] Group 1: Reasons for Repurchase - The repurchase involves 13 out of 14 incentive plan participants, with 10 leaving for personal reasons and 1 having a performance evaluation of B [2][5] - The total number of restricted stocks being repurchased is 220,300, with 21,000 stocks frozen due to legal reasons for one participant [3][6] Group 2: Details of the Repurchase - The repurchase includes 168,700 stocks from the 2022 plan and 72,000 stocks from the 2024 plan, with repurchase prices set at 15.65 yuan and 18.09 yuan per stock respectively [5][6] - The company has opened a dedicated securities account for the repurchase and expects the cancellation to be completed by October 9, 2025 [7] Group 3: Impact on Share Structure - After the repurchase, the remaining restricted stocks will total 6,382,480, and the repurchase will not affect the control of the company [7] Group 4: Compliance and Legal Opinions - The board confirmed that the decision-making process and disclosures comply with relevant regulations and that there are no violations of the rights of incentive participants or creditors [8][9] - Legal opinions affirm that the repurchase has received necessary approvals and complies with applicable regulations [9]